Research
Hormonal
Tirzepatide resulted in greater hemoglobin A1c reduction from baseline compared to placebo and active comparators, with absolute reductions up to 3.02%.
Tirzepatide may be a more effective option for lowering blood sugar in patients with type 2 diabetes.
StrongSupportsmedium confidence
Hemoglobin A1c reduction from baseline was greater with tirzepatide across all studies with absolute reductions up to 3.02%.
Why this rating
Based on the results of seven phase 3 randomized trials.
Source
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice
Courtney L. Bradley et al. · Annals of Pharmacotherapy · 2022
DOI 10.1177/10600280221134127
reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →